NasdaqGS:HALO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. More Details


Snowflake Analysis

Exceptional growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Halozyme Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HALO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.2%

HALO

-3.4%

US Biotechs

-2.4%

US Market


1 Year Return

91.8%

HALO

35.9%

US Biotechs

18.2%

US Market

Return vs Industry: HALO exceeded the US Biotechs industry which returned 39.3% over the past year.

Return vs Market: HALO exceeded the US Market which returned 19.5% over the past year.


Shareholder returns

HALOIndustryMarket
7 Day4.2%-3.4%-2.4%
30 Day6.2%0.7%4.2%
90 Day6.0%-4.7%6.3%
1 Year91.8%91.8%38.3%35.9%20.9%18.2%
3 Year68.5%68.5%18.5%12.5%41.2%31.8%
5 Year106.6%106.6%17.2%8.9%84.8%63.9%

Price Volatility Vs. Market

How volatile is Halozyme Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Halozyme Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HALO ($29.46) is trading below our estimate of fair value ($59.74)

Significantly Below Fair Value: HALO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HALO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: HALO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HALO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HALO is overvalued based on its PB Ratio (38.1x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Halozyme Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

36.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HALO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: HALO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HALO's is expected to become profitable in the next 3 years.

Revenue vs Market: HALO's revenue (26% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: HALO's revenue (26% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HALO's Return on Equity is forecast to be very high in 3 years time (83%).


Next Steps

Past Performance

How has Halozyme Therapeutics performed over the past 5 years?

5.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HALO is currently unprofitable.

Growing Profit Margin: HALO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HALO is unprofitable, but has reduced losses over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare HALO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HALO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: HALO has a negative Return on Equity (-37.6%), as it is currently unprofitable.


Next Steps

Financial Health

How is Halozyme Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: HALO's short term assets ($500.4M) exceed its short term liabilities ($26.1M).

Long Term Liabilities: HALO's short term assets ($500.4M) exceed its long term liabilities ($395.3M).


Debt to Equity History and Analysis

Debt Level: HALO's debt to equity ratio (369.5%) is considered high.

Reducing Debt: HALO's debt to equity ratio has increased from 99.9% to 369.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HALO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HALO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Halozyme Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HALO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HALO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HALO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HALO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HALO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Helen Torley (57 yo)

6.75yrs

Tenure

US$5,857,126

Compensation

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the ...


CEO Compensation Analysis

Compensation vs Market: Helen's total compensation ($USD5.86M) is about average for companies of similar size in the US market ($USD5.61M).

Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Helen Torley
President6.75yrsUS$5.86m0.35%
$ 14.2m
Elaine Sun
Senior VP & CFO0.58yrno datano data
Michael LaBarre
Senior VP & Chief Technical Officerno dataUS$437.90k0.12%
$ 4.7m
Ed Gemo
VP, Chief Information & Security Officer5.75yrsno datano data
Albert Kildani
Vice President of Investor Relations & Corporate Communications1.92yrsno datano data
Masaru Matsuda
Senior VPno datano data0.0084%
$ 337.0k
Amy Fox
Vice President of Human Resources0.75yrno datano data
William Fallon
Senior VP &2.58yrsUS$708.80kno data
Steve Knowles
Chief Medical Officer0.67yrno datano data
Todd Butler
Chief of Staff to the CEO0.92yrno datano data

1.4yrs

Average Tenure

56yo

Average Age

Experienced Management: HALO's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Helen Torley
President6.75yrsUS$5.86m0.35%
$ 14.2m
Connie Matsui
Independent Chairperson of the Boardno dataUS$305.00k0.15%
$ 6.1m
Jeffrey Henderson
Independent Director5.17yrsUS$290.00k0.053%
$ 2.1m
Daniel Von Hoff
Member of the Scientific Advisory Board16.17yrsno datano data
Jeffrey Bleil
Member of the Advisory Boardno datano datano data
Gregory Frost
Chairman of Scientific Advisory Board6.75yrsUS$68.17kno data
Gerhard Baumgartner
Member of Scientific Advisory Board16.33yrsno datano data
James Daly
Independent Director4.58yrsUS$255.00k0.023%
$ 924.2k
Kenneth Kelley
Independent Director16.42yrsUS$275.00k0.21%
$ 8.4m
Sue Bailey
Member of Scientific Advisory Board15.25yrsno datano data
Matthew Posard
Independent Director7.58yrsUS$270.00k0.090%
$ 3.6m
Jean-Pierre Bizzari
Independent Director5.75yrsUS$260.00k0.060%
$ 2.4m

7.2yrs

Average Tenure

61yo

Average Age

Experienced Board: HALO's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HALO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Halozyme Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Halozyme Therapeutics, Inc.
  • Ticker: HALO
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.031b
  • Shares outstanding: 136.82m
  • Website: https://www.halozyme.com

Number of Employees


Location

  • Halozyme Therapeutics, Inc.
  • 11388 Sorrento Valley Road
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HALONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2003
RV7DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2003
0J2OLSE (London Stock Exchange)YesCommon StockGBUSDJan 2003

Biography

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company’s products are based on the ENHANZE drug delivery technol ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 00:06
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.